This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Del Rio, G. Articles by Dal-Re, R. Search for Related Content PubMed PubMed Citation Articles by Del Rio, G. Articles by Dal-Re, R.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, Feb 1996, 408-412, Vol 40, No. 2
Copyright © 1996 by the American Society for Microbiology. All rights reserved.

Single-dose rufloxacin versus 3-day norfloxacin treatment of uncomplicated cystitis: clinical evaluation and pharmacodynamic considerations

G Del Rio, F Dalet, L Aguilar, J Caffaratti and R Dal-Re
Nephrology Department, Fundacion Puigvert, Barcelona, Spain.

The efficacy and safety of rufloxacin (400 mg, single dose) were compared to those of norfloxacin (400 mg twice a day for 3 days) for the treatment of women with uncomplicated cystitis. In addition, urine levels, drug level/MIC ratio, and urine antibacterial activity 72 to 84 h after treatment initiation were determined in a subgroup of patients for pharmacodynamic assessment. A total of 203 women were included and treated in this open, randomized clinical trial; 100 patients received norfloxacin, whereas 103 received rufloxacin. Of these, 156 (74 and 82 patients in the norfloxacin and rufloxacin groups, respectively) were considered bacteriologically evaluable. At the first follow-up visits (3 to 12 days after starting the treatment), bacteriological cure rates were 99 and 94% for norfloxacin and rufloxacin, respectively. Seventy- nine percent (119 of 150) of bacteriologically cured patients attended a long-term follow-up visit (4 to 6 weeks after starting the treatment), where a relapse rate of 4% (2 of 54) and 5% (3 of 64) were found in the norfloxacin and rufloxacin groups, respectively. The pharmacodynamic evaluation performed in 35 patients showed similar median urine levels (approximately equal to 25 micrograms/ml) and urine antibacterial activity for both treatment groups against initial isolates, despite a higher norfloxacin level/MIC ratio due to the lower MIC of norfloxacin. Twenty-one patients (20%) in the rufloxacin group and 12 patients (12%) in the norfloxacin group reported 39 and 16 adverse events, respectively, almost all of them being mild and lasting < 24 h. Overall, gastrointestinal reactions were the most frequent adverse events reported. However, 12 patients treated with rufloxacin reported 15 central nervous system adverse events. This study shows that single doses of rufloxacin are as effective as a norfloxacin 3-day standard treatment in uncomplicated cystitis. The results obtained with rufloxacin are consistent with its pharmacodynamic properties.

This article has been cited by other articles:

• Alou, L., Aguilar, L., Sevillano, D., Gimenez, M.-J., Cafini, F., Valero, E., Relano, M.-T., Prieto, J. (2006). Urine bactericidal activity against resistant Escherichia coli in an in vitro pharmacodynamic model simulating urine concentrations obtained after 2000/125 mg sustained-release co-amoxiclav and 400 mg norfloxacin administration. J Antimicrob Chemother 57: 714-719 [Abstract] [Full Text]  
• Vicari, E. (2000). Effectiveness and limits of antimicrobial treatment on seminal leukocyte concentration and related reactive oxygen species production in patients with male accessory gland infection. Hum Reprod 15: 2536-2544 [Abstract] [Full Text]  
• Kinzig-Schippers, M., Fuhr, U., Cesana, M., Müller, C., Staib, A. H., Rietbrock, S., Sörgel, F. (1998). Absence of Effect of Rufloxacin on Theophylline Pharmacokinetics in Steady State. Antimicrob. Agents Chemother. 42: 2359-2364 [Abstract] [Full Text]